Cell couriers offer clue to how cancers metastasize into secondary tumors

A protein involved in making cells move offers a clue to how certain types of cancer metastasize and develop into secondary tumors, according to new research from the University of Warwick.

Scientists from Warwick Medical School have demonstrated for the first time that levels of this protein can increase and decrease the movement of a cell, including cancer cells - suggesting that they could play a role in the spread of tumors.

The study is published today (21 July) in the Journal of Cell Biology and was funded by the Medical Research Council, part of UK Research and Innovation.

The researchers are investigating a tiny cell component called an Intracellular nanovesicle (INV) which acts like a courier within a cell by transporting cargo to where it is needed. When a cell moves, the INV moves a particle called an integrin from the cell's surface to 'unstick it' from the surface it is attached to. It then recycles and replaces the integrin to stick it to a new surface.

INVs have a protein called Tumor Protein D54, increased levels of which have been associated with certain types of breast cancer and often a poor prognosis for the patient. These patients tend to have more metastases, where tumor cells spread to other parts of the body.

To investigate TPD54's role in cell movement, the Warwick team observed cells migrating on a surface coated with fibronectin, a type of extra-cellular matrix, using a live cell microscope. They then reduced or increased the expression of the protein TPD54 to mimic the expression in a cancer cell, observing how the cell migrates more or less depending upon the levels of TPD54.

They also conducted the same experiment using ovarian cancer cells inside a 3D mesh rich in fibronectin, a more accurate representation of how a cell would behave inside a tumor. When they depleted the levels of the TPD54 protein, the scientists could see that the cells migrated less.

Lead author Professor Stephen Royle, of Warwick Medical School at the University of Warwick, said: "There are circumstances where you don't want cells to move around, such as in cancer. We show in this paper that if you decrease the levels of the TPD54 protein then cells move less, and if you increase the levels they move more. It offers an explanation for why cancer cells that have overexpression of this protein tend to be more metastatic and spread.

"The name Tumor Protein D54 comes from the fact that it is overexpressed in cancer but not a lot is known about it at the molecular level. We have found how this protein attaches to INVs inside cells and controls what cells normally do."

Despite its name, Tumor Protein D54 is involved in a number of normal processes of a cell, and is also involved in the immune response, wound healing, and other functions. The research suggests that TDP54 would not be an ideal target for a cancer intervention due to its role in these normal functions of the cell, but it does give scientists a better understanding of how integrin trafficking is altered in cancer.

This protein is actually a healthy protein. It's needed for these INVs to move around, to move other cargoes, and perform other functions besides migration. It's one of the most highly expressed proteins in normal cells which indicates that it's probably doing something important. We think it has something to do with this army of INV couriers working within a cell.

But in cancer, we've suddenly got lots of couriers trafficking lots of integrins, and so we get more movement of cells and that's not good. If you've got cancer cells, you don't want them to migrate."

Professor Stephen Royle, Lead Author

The Warwick group discovered INVs in 2019, having previously been overlooked. At around 30 nanometers across, they were so small that the team had to use a combination of electron microscopy and the Warwick Open Source Microscope, a super-resolution light microscope built at the University of Warwick, to observe them.

Professor Royle adds: "They were hiding in plain sight - you can go back to micrographs from the fifties and can see that they were there, it's just we didn't have the tools to find them.

"The bigger question for us is how these vesicles behave and what they carry. They carry a whole range of other proteins and they are likely involved in lots of other cell functions. The thinking within the field is that cargoes like integrins are trafficked in very large tubules, but we're showing that it's actually happening in these smaller vesicles."

Journal reference:

Larocque, G., et al. (2021) Intracellular nanovesicles mediate α5β1 integrin trafficking during cell migration. Journal of Cell Biology. doi.org/10.1083/jcb.202009028.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    The University of Warwick. (2022, December 14). Cell couriers offer clue to how cancers metastasize into secondary tumors. AZoLifeSciences. Retrieved on May 17, 2024 from https://www.azolifesciences.com/news/20210722/Cell-couriers-offer-clue-to-how-cancers-metastasize-into-secondary-tumors.aspx.

  • MLA

    The University of Warwick. "Cell couriers offer clue to how cancers metastasize into secondary tumors". AZoLifeSciences. 17 May 2024. <https://www.azolifesciences.com/news/20210722/Cell-couriers-offer-clue-to-how-cancers-metastasize-into-secondary-tumors.aspx>.

  • Chicago

    The University of Warwick. "Cell couriers offer clue to how cancers metastasize into secondary tumors". AZoLifeSciences. https://www.azolifesciences.com/news/20210722/Cell-couriers-offer-clue-to-how-cancers-metastasize-into-secondary-tumors.aspx. (accessed May 17, 2024).

  • Harvard

    The University of Warwick. 2022. Cell couriers offer clue to how cancers metastasize into secondary tumors. AZoLifeSciences, viewed 17 May 2024, https://www.azolifesciences.com/news/20210722/Cell-couriers-offer-clue-to-how-cancers-metastasize-into-secondary-tumors.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New optical tool controls bacterial electrical signaling